Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)

Intellia Therapeutics (NTLA) has reported Assets Average for 11 consecutive years, with $800.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 26.47% year-over-year to $800.5 million; the TTM figure through Mar 2026 stood at $800.5 million (down 26.47% YoY), while the FY2025 annual figure was $1.0 billion, down 18.41% from the prior year.
• Assets Average retreated to $800.5 million in Q1 2026 per NTLA's latest filing, from $883.7 million in the prior quarter.
• Across five years, Assets Average topped out at $1.5 billion in Q1 2023 and bottomed at $800.5 million in Q1 2026.
• Historically, Assets Average has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• Annual changes were most pronounced in 2022 — Assets Average soared 79.24% — and 2026, when it retreated 26.47%.
• Intellia Therapeutics' Assets Average stood at $1.3 billion in 2022, then fell by 2.31% to $1.3 billion in 2023, then dropped by 7.07% to $1.2 billion in 2024, then dropped by 25.25% to $883.7 million in 2025, then dropped by 9.42% to $800.5 million in 2026.
• Business Quant data shows NTLA's Assets Average at $800.5 million in Q1 2026, $883.7 million in Q4 2025, and $912.1 million in Q3 2025.